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Abstract
Problem/Condition: Pulmonary hypertension, which is listed on hospital records and death certificates as either
primary (i.e., idiopathic) pulmonary hypertension or pulmonary hypertension secondary to another underlying
condition or disease, is considered rare amongst the U.S. population. Limited reports have been published re-
garding surveillance data for this debilitating and often fatal condition.
Reporting Period Covered: 1980–2002.
Description of Systems: This report summarizes mortality data from the National Vital Statistic System (NVSS)
and hospital discharge data from the National Hospital Discharge Survey (NHDS) for 1980–2002 and Medicare
hospital claims data for 1990–2002. NVSS, maintained by CDC’s National Center for Health Statistics (NCHS),
compiles multiple cause of death information from official death certificates filed in the United States. NHDS,
also conducted annually by NCHS, includes information on discharges from a sample of nonfederal, short-stay
hospitals. Annual hospital claims and enrollment data for all Medicare beneficiaries aged >65 years are provided
by the Center for Medicare and Medicaid Services. Because pulmonary hypertension might be reported second-
ary to other diseases, this report presents data for pulmonary hypertension as any contributing cause of death or
any-listed hospital diagnosis.
Since 1980, the numbers of deaths and hospitalizations, death rates, and hospitalization rates have increased for
pulmonary hypertension, particularly among women and older adults. During 1980–2000, death rates were
higher for men than women; however, by 2002, no difference in rate was observed because of increasing death
rates among women and declining death rates among men. Hospitalization rates were higher for men than for
women until 1995; after 1995, higher rates were observed among women. Death rates since 1985 and Medicare
hospitalization rates throughout the reporting period 1990–2002 have been higher for blacks than for whites. In
addition, two distinct geographic clusters were observed for the highest hospitalization rates in the Medicare
population and the highest death rates for pulmonary hypertension, in the western United States and in the
Appalachian region.
Interpretation: Increases in mortality from and hospitalization for pulmonary hypertension might reflect in-
creased physician awareness and changes in diagnosing and reporting this chronic disease. Although pulmonary
hypertension historically has been considered a disease of women of childbearing age, it affects all ages and racial
populations. Older women represent the majority of patients and decedents with this condition. More research is
needed concerning cause, prevention, and treatment of
pulmonary hypertension. Public health initiatives should
include increasing physician awareness that early detec-
tion is needed to initiate prompt, effective disease man-
agement. Additional epidemiologic initiatives also are
needed to ascertain prevalence and incidence of various
pulmonary hypertension disease entities such as
pulmonary arterial hypertension.
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Introduction
Pulmonary hypertension is a hemodynamic state signifying
the presence of one or more pulmonary vascular disease enti-
ties and is characterized by a severe elevation in the mean pul-
monary arterial pressure and pulmonary vascular resistance
(1). Because early symptoms (i.e., difficulty in breathing and
fatigue) and later manifestations (i.e., reduced exercise toler-
ance, palpitations, fainting, swelling of the ankles or legs, chest
pain, or hoarseness) are symptomatic of other diseases, prompt
diagnosis and treatment can be delayed because physicians
often have to exclude other causes for these symptoms (2–4).
Pulmonary hypertension is a devastating chronic disease with
a poor long-term prognosis; results from a national registry of
patients with primary (i.e., idiopathic) pulmonary hyperten-
sion indicated that the duration from onset of symptoms to
death was an average of 2.8 years (5). In recent years, new
treatments have become available for primary pulmonary hy-
pertension, particularly for pulmonary arterial hypertension,
which include anticoagulants, calcium channel blockers, and
prostacyclins (3,4,6–12); these treatments prolong survival and
provide clinical improvement but can often be expensive. Al-
though effective management might be possible with early
detection, the majority of persons have pulmonary hyperten-
sion diagnosed in later stages of the disease, making treatment
more difficult and less successful.
Pulmonary hypertension is reported on hospital records and
death certificates as either primary pulmonary hypertension or
as pulmonary hypertension secondary to another underlying
condition or disease. Pulmonary hypertension might be sec-
ondary to congenital heart disease, valvular heart disease, chronic
thromboembolic disease, lung diseases, liver diseases, sleep-
disordered breathing and hypoxemia, lupus, scleroderma, rheu-
matoid arthritis, vasculitis, or human immunodeficiency virus
(HIV) infection (3,7,13). Traditionally, primary pulmonary
hypertension might have been diagnosed when no obvious cause
of death could be identified. The traditional classification of
primary or secondary pulmonary hypertension has limitations
and has not been useful in clinical practice (4). In 1998, a con-
ference sponsored by the World Health Organization proposed
a new treatment-oriented classification of all pulmonary hyper-
tensive diseases rather than addressing only primary pulmo-
nary hypertension (4,14). Therefore, this report will focus on
all forms of pulmonary hypertension.
Limited national statistics are available regarding pulmo-
nary hypertensive diseases (15,16). Although a rare condition,
death rates for primary pulmonary hypertension as the un-
derlying cause of death have increased since 1979 (15), and
the number of all cases is likely higher than that reported be-
cause of difficulties in disease detection (16). This report de-
scribes trends during 1980–2002 in diagnosed pulmonary
hypertension–related deaths and hospitalizations, the only
national surveillance data available for pulmonary hyperten-
sion. Because pulmonary hypertension might be more likely
to be reported secondary to other diseases, this report pre-
sents data for pulmonary hypertension as any contributing
cause of death or as any-listed hospital diagnosis.
Methods
For this analysis, pulmonary hypertension included primary
pulmonary hypertension (i.e., idiopathic pulmonary arterio-
sclerosis, idiopathic or primary pulmonary artery hypertension,
and essential or idiopathic pulmonary hypertension); second-
ary pulmonary hypertension; other specified pulmonary heart
disease, including a small number of cardiopulmonary events;
and unspecified chronic pulmonary heart disease, including
chronic cardiopulmonary disease and chronic cor pulmonale
(17–19). To examine trends in pulmonary hypertension, CDC
analyzed data from the National Vital Statistics System (NVSS),
the National Hospital Discharge Survey (NHDS), and
Medicare hospital claims and enrollment records.
Mortality Data
NVSS, which is maintained by the National Center for
Health Statistics (NCHS), compiles data from vital records
on all deaths occurring annually in the United States. Public
use data from NVSS files provide the underlying cause of death
and up to 19 additional contributing causes and demographic
data on decedents (20). Demographic data on death certifi-
cates are reported by funeral directors, usually from informa-
tion provided by family members of decedents. A physician,
medical examiner, or coroner reports on the death certificate
the diseases, injuries, or complications that caused the death.
The underlying cause of death is the disease (or injury) that
initiated the sequence of events leading directly to death. For
this analysis, all diseases and conditions reported on death
certificates were classified according to codes from the Inter-
national Classification of Diseases, Ninth Revision (ICD-9) for
deaths during 1980–1998 (17) and codes from the Interna-
tional Classification of Diseases, Tenth Revision (ICD-10) for
deaths during 1999–2002 (18,19). Pulmonary hypertension
was diagnosed for decedents with ICD-9 codes 416.0, 416.8,
or 416.9 during 1980–1998 or ICD-10 codes I27.0, I27.8,
or I27.9 during 1999–2002 reported as any contributing cause
of death (i.e., any of the possible 20 conditions, including
underlying cause) on the death certificate.
Numbers of U.S. residents for the period 1980–2002 were
provided by the U.S. Bureau of the Census and used to calcu-
late death rates per 100,000 population. Bridged-race Census
estimates were used as denominators for groups defined by
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race and Hispanic origin during 1990–2002 (20). Death rates
were age-standardized to the 2000 U.S. standard population
(21,22). Age-specific death rates were calculated for groups
aged <45, 45–54, 55–64, 65–74, 75–84, and >85 years. Be-
fore 1990, race categories on Census data included only white,
black, and other race; beginning in 1990, race categories in-
cluded white, black, Asian/Pacific Islander, and American
Indian/Alaska Native. Hispanic origin was also included in
Census data beginning in 1990. Because numbers of deaths
with pulmonary hypertension as a contributing cause were
relatively small each year, data were aggregated into four 5-year
periods (1980–1984, 1985–1989, 1990–1994, and 1995–
1999) and one 3-year period (2000–2002) to examine dece-
dent characteristics and age-specific and -standardized death
rates among groups defined by race, sex, or age. For 2000–
2002, data were aggregated for all 50 states and the District of
Columbia (DC) to examine geographic variations in deaths
with pulmonary hypertension as a contributing cause.
The distribution of selected disease categories reported as
the underlying cause of death among decedents with reported
pulmonary hypertension was examined for each period. These
disease categories were selected based on reported associations
of particular diseases with pulmonary hypertension. A major
category of interest was chronic lower respiratory disease (e.g.,
chronic bronchitis, unspecified bronchitis, emphysema,
asthma, and other chronic lower respiratory diseases), of which
encompasses chronic obstructive pulmonary disease (23).
Hospitalizations
NHDS is conducted annually by NCHS and provides de-
mographic and discharge information abstracted from medi-
cal records of inpatients selected from a nationally
representative sample of nonfederal, short-stay hospitals in the
50 states and DC (24,25). Only hospitals with six or more
staffed beds and an average length of patient stay of <30 days
or those with a general (i.e., medical or surgical) specialty or
children’s specialty were included in the survey (25). Estimates
of the number and rate of hospitalizations attributed to pul-
monary hypertension (International Classification of Diseases,
Ninth Revision, Clinical Modification [ICD-9-CM] codes
416.0, 416.8, or 416.9 [26]) are provided in this report. These
estimates are based on counting a patient if a diagnosis is de-
termined as any one of the up to seven medical diagnoses
recorded in NHDS. Estimates from NHDS were calculated
by using the weights (i.e., inflation factors) that allow estima-
tion from the sample.
Data on the U.S. civilian population for the period 1980–
2002 were obtained from the U.S. Bureau of the Census and
used to calculate age- and sex-specific hospitalization rates per
100,000 population. Age-specific hospitalization rates were
calculated for persons aged <45, 45–54, 55–64, 65–74, 75–
84, and >85 years. Hospitalization rates for pulmonary hy-
pertension as any-listed diagnosis were age-standardized to the
2000 U.S. standard population (21,22). To examine trends in
hospitalizations during 1980–2002, data were aggregated into
four 5-year periods (1980–1984, 1985–1989, 1990–1994,
and 1995–1999) and one 3-year period (2000–2002). Race-
specific estimates are not provided because of incomplete re-
porting of race on hospital records (27). In addition, the
sampling design for NHDS does not provide for state-spe-
cific estimates of hospitalizations. The distribution of selected
disease categories as the principal (i.e., first listed) diagnosis
also was examined for each period among hospitalizations with
any-listed pulmonary hypertension.
Medicare Claims
Medicare hospital claims represent the only available source
of hospital discharge information for racial populations and
all states and DC. All Medicare hospital claims and enroll-
ment record data for 1990–2002 were obtained from the Cen-
ters for Medicare and Medicaid Services. A hospitalization for
pulmonary hypertension was defined as one for which any of
up to 10 diagnoses (five diagnoses in 1990) on the hospital
claim was classified as an ICD-9-CM code 416.0, 416.8, or
416.9. The number of persons at risk (i.e., U.S. residents in
the 50 states and DC aged >65 years who were entitled to
Medicare Part A benefits on July 1 during 1990–2002, ex-
cluding members of health maintenance organizations) was
obtained from Medicare enrollment records. Hospitalization
rates per 100,000 Medicare enrollees were age-standardized
to the 2000 U.S. standard population aged >65 years (21,22).
Age-specific hospitalization rates were calculated for groups
aged 65–74, 75–84, and >85 years. Race categories on hospi-
tal claims and enrollment records included white, black, Asian,
Hispanic, and American Indian. State-specific numbers were
obtained, and age-standardized rates of hospitalizations with
pulmonary hypertension as any-listed diagnosis were calcu-
lated for the Medicare population in all 50 states and DC.
Results
Mortality Data
During 1980–2002, the total number of deaths attributed
to pulmonary hypertension as any contributing cause of death
increased from 10,922 to 15,668 (Table 1); however, the in-
crease was observed only among women. During 1980–1991,
women had lower numbers of deaths from pulmonary hyper-
tension than men; after 1991, women had higher numbers of
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deaths than men. Age-standardized death rates for the total
U.S. population remained relatively stable from 1980 (5.2
per 100,000) through 2002 (5.4 per 100,000) (Table 1).
However, rates increased among women but decreased among
men during this period such that the age-standardized death
rates were similar beginning in 2000 (Figure 1). Among all
racial populations, the number of deaths from pulmonary
hypertension reported as any contributing cause of death in-
creased, with blacks having the highest age-standardized death
rates (Table 2, Figure 2). Non-Hispanics had higher age-
standardized death rates than Hispanics (Table 3). Age-
specific death rates for pulmonary hypertension reported as
any contributing cause of death also increased, primarily
among adults aged >85 years, particularly during 1990–2002
(Table 4, Figure 3).
The annual number of deaths from pulmonary hyperten-
sion as any contributing cause of death was aggregated into
the five selected periods (1980–1984, 1985–1989, 1990–
1994, 1995–1999, and 2000–2002) for groups defined by
sex, age, race, and Hispanic ethnicity to obtain stable esti-
mates for comparisons. Over the five periods, age-
standardized death rates for pulmonary hypertension as any
contributing cause of death increased among women and
blacks (Table 5). Age-specific death rates increased among men
aged >85 years, women aged >65 years, whites aged >75 years,
and blacks aged >65 years (Table 5). Nevertheless, during
2000–2002, men had slightly higher age-specific death rates
than women in the older age groups (Figure 4). At ages <75
years, blacks had higher age-specific death rates than whites
during 2000–2002, but whites had higher death rates than
blacks at ages >85 years (Figure 5).
During 2000–2002, age-standardized death rates for pul-
monary hypertension reported as any contributing cause of
death varied among states/areas (Table 6). States/areas with
the highest age-standardized death rates were Wyoming (9.9),
Idaho (8.9), DC (8.8), Colorado (8.6), Vermont (8.4), Alaska
(7.7), Montana (7.4), North Carolina (7.4), Ohio (7.4), West
Virginia (7.3), and New Hampshire (7.2).
During 1980–2002, because of increased numbers of death
among women, the proportion of decedents with reported
pulmonary hypertension who were female increased. During
2000–2002, 58.3% of all decedents with pulmonary hyper-
tension reported on their death certificates were female
(Table 7). Among decedents with reported pulmonary hyper-
tension, the proportion whose race was reported as black also
increased.
Among decedents with pulmonary hypertension reported,
little change was observed in the proportions of those who
were aged <55 years. However, the proportion of decedents
aged >75 years increased during 1980–2002 such that 30.6%
of all decedents with pulmonary hypertension reported dur-
ing 2000–2002 were aged 75–84 years and 18.1% were aged
>85 years, compared with 23.7% and 6.5%, respectively, dur-
ing 1980–1984 (Table 7). Age distributions were similar
among females and males aged <55 years during 2000–2002
(Figure 6); however, 21% of all female decedents with pul-
monary hypertension reported were aged >85 years, compared
with 14% of male decedents, although greater proportions of
men than women were aged 65–74 years. Only 11.1% of male
decedents and 9.6% of female decedents with pulmonary hy-
pertension reported during 2000–2002 were aged <45 years,
an age category that includes women of childbearing age
affected by pregnancy-related pulmonary hypertension and
newborns and young children with congenital anomalies or
familial pulmonary hypertension. In contrast, a higher pro-
portion of decedents were aged <45 years among blacks com-
pared with whites (22.4% versus 8.0%) during 2000–2002
(Figure 7). The proportions who were aged 45–54 years and
55–64 years were higher among blacks than among whites; in
contrast, the proportion who were aged >65 years was higher
among whites than among blacks during 2000–2002 (75.1%
versus 48.2%, respectively).
Some disease categories that are commonly reported with
pulmonary hypertension were rarely reported as the underly-
ing cause of death among decedents (Table 8). During 2000–
2002, among decedents with pulmonary hypertension
reported on the death certificate, the most commonly reported
underlying cause was pulmonary hypertension (30.3%), fol-
lowed by chronic lower respiratory disease (25.9%). During
1980–2002, the proportions of decedents with pulmonary
hypertension reported as the underlying cause of death in-
creased among all decedents with pulmonary hypertension
reported as any cause on the death certificate. Although chronic
lower respiratory disease was the most commonly reported
underlying cause of death for persons with pulmonary hyper-
tension during 1980–1984 (49.2%), the proportion decreased
during 1980–2002. The increase in reported pulmonary hy-
pertension and the decline in reported chronic lower respira-
tory disease as the underlying cause of death among all
decedents with pulmonary hypertension reported were ob-
served in all groups defined by sex, race, and age. Among de-
cedents aged <45 years, the most common underlying causes
of death were pulmonary hypertension; congenital malfor-
mations; complications of pregnancy, childbirth, and the
puerperium, or conditions originating in the perinatal period;
and other cardiovascular diseases (Table 9).
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Hospitalizations
During 1980–2002, the estimated number of hospitaliza-
tions with pulmonary hypertension as any-listed diagnosis
tripled for the total U.S. population (Table 10). Compared
with estimated numbers of hospitalizations in 1980, the num-
bers in 2002 were two times higher among men and four times
higher among women. Age-standardized hospitalization rates
doubled for men and tripled for women. Rates of hospitaliza-
tions for pulmonary hypertension among women were higher
than those for men, only after 1995 (Figure 8). In 2002, the
age-standardized hospitalization rate for pulmonary hyperten-
sion as any-listed diagnosis was 95.3 for women and 82.3 for
men. Numbers of hospitalizations and age-specific hospital-
ization rates increased for all age groups in the total U.S. popu-
lation (Table 11). The greatest increase in hospitalization rate
was among adults aged >75 years (Figure 9).
To examine trends by sex and age, sample sizes were in-
creased to obtain more reliable estimates by aggregating years
of data from NHDS. During 1980–2002, the greatest increase
was for ages >85 years among men and for ages >65 years
among women (Table 12). Because of major increases in hos-
pitalizations among women aged >85 years, during 2000–
2002, women had higher hospitalization rates than men in
this older age group (Figure 10).
During 1980–2002, because of substantial increases in the
number of women hospitalized with pulmonary hypertension,
the proportion increased such that 60.6% of all hospitaliza-
tions with any-listed diagnosis of pulmonary hypertension
during 2000–2002 were among women (Table 13). During
the 2 decades, the proportion of patients aged >65 years in-
creased from 55.4% during 1980–1984 to 66.0% during
2000–2002 among all hospitalizations with pulmonary hy-
pertension as any-listed diagnosis. During 2000–2002, the
proportion of hospitalized persons aged >85 years was higher
among women than men (Figure 11).
During 1980–2002, trends in the most commonly reported
principal diagnosis changed (Table 14). During 1980–1984,
the most commonly reported principal diagnoses among hos-
pitalizations with any-listed diagnosis of pulmonary hyper-
tension were chronic lower respiratory diseases (42.0%),
followed by pulmonary hypertension (12.8%) and other car-
diovascular diseases (6.8%). By 2000–2002, heart failure
(18.7%) was the most commonly reported principal diagno-
sis, followed by chronic lower respiratory diseases (12.9%)
among hospitalizations with any-listed diagnosis of pulmo-
nary hypertension. During 2000–2002, pulmonary hyperten-
sion was the principal diagnosis of only 4.2% of
hospitalizations involving pulmonary hypertension as any-
listed diagnosis. Declines in reporting pulmonary hyperten-
sion and chronic lower respiratory disease and the increase in
reporting heart failure as the principal diagnosis in these cases
were observed among all groups defined by sex and age. Among
persons aged <45 years, the principal diagnosis was more likely
to be pulmonary hypertension (26.0%) and congenital mal-
formations (22.9%) during 1980–1984; however, by 2000–
2002, these conditions had declined as the principal diagnosis
among hospitalizations with pulmonary hypertension as any-
listed diagnosis (Table 15). Other cardiovascular diseases
(29.8%), other respiratory diseases (9.8%), pulmonary hy-
pertension (9.5%), and chronic lower respiratory diseases
(7.1%) were the major principal diagnoses during 2000–2002.
During this period, other frequently reported principal diag-
noses were examined for these pulmonary hypertension hos-
pitalizations among patients aged <45 years. Influenza and
pneumonia (4.6%), congenital malformations (4.3%), com-
plications related to specific procedures (3.9%), cellulites and
abscess (3.6%), and complications related to pregnancy and
childbirth (3.2%) also were principal diagnoses for these
younger patients.
Medicare Claims
During 1990–2002, the annual number of hospitalizations
for pulmonary hypertension as any-listed diagnosis tripled
among Medicare enrollees aged >65 years, from 55,516 to
187,205 (Table 16). The age-standardized hospitalization rate
was 197.8 in 1990 and 649.7 in 2002. Men had higher age-
standardized Medicare hospitalization rates with any-listed
pulmonary hypertension than women until 1999 (Figure 12).
Increases in numbers of Medicare hospitalizations for pulmo-
nary hypertension were observed among all groups defined
by race (Table 17) and age (Table 18). Age-standardized
hospitalization rates were higher for blacks than whites
(Figure 13). Age-specific hospitalization rates increased for all
age groups, but the rates were not the highest among adults
aged >85 years until after 1995 (Figure 14). By 2000–2002,
age-specific hospitalization rates were higher among women
at ages 65–74 years and 75–84 years, and whites had higher
age-specific hospitalization rates than blacks at ages >85 years
(Table 19).
During 1990–2002, age-standardized Medicare hospitaliza-
tion rates increased each year in each state. State data were
aggregated for 2000–2002 to obtain more stable Medicare
hospitalization rates (Table 20). During 2000–2002, states/
areas with the highest age-standardized hospitalization rates
with pulmonary hypertension as any-listed diagnosis were
Wyoming (1172.1), Colorado (1022.8), West Virginia
(954.7), Pennsylvania (907.0), Maryland (841.1), Montana
(833.2), Idaho (796.3), New Mexico (792.5), Virginia (788.3),
DC (782.0), and Delaware (781.7).
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Discussion
The findings in this report indicate that, during 1980–2002,
death rates and hospitalization rates for pulmonary hyperten-
sion as either any contributing cause of death or as any-listed
hospital diagnosis increased. The number of pulmonary
hypertension–related deaths and number of hospitalizations
also increased, particularly among women, blacks, and older
adults. Nevertheless, death rates were higher for men than
women during the 2 decades, and hospitalization rates were
higher for men than women until 1995. A geographic clus-
tering of the highest Medicare hospitalization rates and high-
est death rates for pulmonary hypertension was observed in
the western United States (in Colorado, Idaho, Montana, and
Wyoming) and a second clustering in the Appalachian region
(in DC, Maryland, Pennsylvania, Virginia, and West Virginia).
In addition, reporting of pulmonary hypertension as the un-
derlying cause of death increased, and reporting pulmonary
hypertension as the principal diagnosis decreased during 1980–
2002. Among all decedents and all persons hospitalized with
pulmonary hypertension, the reporting of chronic lower res-
piratory disease (including chronic obstructive pulmonary
disease) as the underlying cause of death or principal hospital
diagnosis declined, and reporting heart failure as the princi-
pal diagnosis on the hospital record increased for all age groups.
Increases in reporting pulmonary hypertension as any-listed
diagnosis on hospital records might indicate an actual increase
in the number of patients or, more likely, a greater increased
awareness among physicians to evaluate and diagnose pulmo-
nary hypertension. In 1996, studies suggested a link between
appetite suppressants and increases in primary pulmonary
hypertension (28–30), which probably created greater public
and professional interest in the disease, particularly in terms
of cases among women. Hospitalization rates for pulmonary
hypertension began increasing among both men and women
during the early 1990s at the same time that use of appetite
suppressants was prevalent (31); however, the major increases
in hospitalization rates with pulmonary hypertension as any-
listed diagnosis seem to have occurred among older women
than among younger and middle-aged women who were more
likely to take suppressants (32).
As the reporting of chronic lower respiratory disease as the
underlying cause of death and principal hospital diagnosis
declined, heart failure as the principal diagnosis on hospital
records and the reporting of pulmonary hypertension as the
underlying cause of death on death certificates increased.
Changes in the reporting of pulmonary hypertension as the
underlying cause of death might be related to changes in medi-
cal opinion and interpretation of certification instructions. In
addition, increased perception of a condition as serious or fa-
tal could lead to increased reporting of that condition as a
contributing cause of death (33) or hospitalization. Heart fail-
ure is rarely reported on death certificates as the underlying
cause because specific instructions on the death certificate state
that “cardiac failure” should not be listed as the underlying
cause of death. Whether these patterns reflect reporting trends
on the part of physicians and health-care systems or actual
changes in the etiology and prevalence of pulmonary hyper-
tension should be investigated further. Nevertheless, efforts
to eliminate underdiagnosis of pulmonary hypertension and
improve the reporting on death certificates and hospital records
must be systematic to obtain a more credible estimate of the
true distribution of pulmonary hypertension in the
U.S. population.
At least three possible explanations exist for the geographic
clusterings of Medicare hospitalizations and death rates for
pulmonary hypertension in the western United States and
Appalachian region. First, differences may exist in medical
opinion on certification instructions or on the number of
causes to be reported per death certificate. Second, these cases
might be more likely to be detected by physicians affiliated
with recognized pulmonary hypertension centers of excellence
and referral that are located in Denver (CO), Baltimore (MD),
and Philadelphia (PA). Third, particular genetic factors or
environmental toxins might be more prevalent in those re-
gions. For example, higher hospitalization rates for pulmo-
nary hypertension in the Medicare population in states
bordering the Appalachian region might reflect higher pro-
portions of the population who were employed in the coal-
mining industry decades ago and who might have contracted
respiratory diseases such as “coal-workers” pneumoconiosis,
diseases that predispose to pulmonary hypertension. In addi-
tion, altitude might also play an important role in the devel-
opment of pulmonary hypertension in states such as Colorado,
Montana, and Wyoming. Identification of these unreported
clusters warrants further investigations.
The findings in this report are subject to at least six limita-
tions. First, mortality data are subject to diagnosis and report-
ing errors by physicians, medical examiners, and coroners,
particularly in the absence of an autopsy. Second, the current
ICD classifications do not allow data users or those reporting
the causes of death and diagnoses to differentiate specific dis-
eases that are of interest in the study of pulmonary hyperten-
sion. For example, approximately 99% of all heart failure
diagnoses documented in this report were congestive heart
failure, a category which also includes right heart failure sec-
ondary to left heart failure; however, isolated right heart fail-
ure and isolated left heart failure do not have reportable codes
but could be of greater interest to future investigators. Simi-
larly, the current ICD codes do not allow differentiation of
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the five major categories of pulmonary hypertension entities
(Table 21). Thus, population estimates for pulmonary
arterial hypertension cannot be ascertained, although this cat-
egory might be of greater interest to current and future re-
search. Third, NHDS does not include patients admitted to
government hospitals (i.e., Veterans Affairs or military); there-
fore, results might underestimate the total number of hospi-
talizations for pulmonary hypertension among adults. Fourth,
the use of hospital discharge records and Medicare claims
records includes the possibility that trends in hospitalization
rates could reflect patterns in financial incentives to report
other diseases as the principal diagnosis rather than pulmo-
nary hypertension. Fifth, hospital discharge data should not
be used to represent prevalence or incidence of the disease
because distinguishing between first or new hospitalizations
or multiple readmissions during the year is not possible. Fi-
nally, a limitation of hospital discharge records and Medicare
hospital claims is the inability to determine the accuracy of
physician or administrative reporting or the validity of ICD
classification of the various disease entities; no information
on results of clinical diagnostic evaluations is available.
Whether pulmonary hypertension is rare is debatable given
the likely underdiagnosis and, thus, underreporting of per-
sons with the disease.
Pulmonary hypertension has had an unclear pathogenesis
(13,34–37). Although advances have occurred in understand-
ing the pathogenesis of pulmonary hypertension among spe-
cialists in the past decade, this understanding might not have
reached general practice. In 1998, a World Health
Organization symposium developed a more inclusive and clini-
cally useful treatment-based classification system that divided
the causes of pulmonary hypertension into five distinct cat-
egories of disease entities (5,14). Unfortunately, this classifi-
cation system has not been translated into useful ICD
classifications for reporting and distinguishing specific dis-
ease entities for surveillance purposes. In 2003, another sym-
posium assessed the impact and usefulness of this classification
and determined that, although the new classification was ac-
cepted and widely used among specialists and in centers with
the largest clinical experience, less experienced physicians ap-
parently continued to use the old classification (i.e., primary
versus secondary) (38). Therefore, this could complicate
prompt evaluation and diagnosis and lead to further misdiag-
nosis and inaccurate reporting on death certificates and hos-
pital records. Continued clinical research is underway to better
understand pulmonary hypertension and its risk factors, as
well as the prevention and treatment of pulmonary hyperten-
sion. However, professional education efforts should be con-
sidered to prompt physician recognition of the early symptoms
of suspected pulmonary hypertension, to inform physicians
about the treatment-based classification of disease entities, and
to educate physicians about the multiple diagnostic evalua-
tions necessary for the categorization and appropriate treat-
ment of patients.
A 2-year delay can occur between onset of symptoms and
diagnosis (12); however, new treatment modalities have been
determined to improve the prognosis of this disease (11). In
addition to the use of anticoagulants and vasodilators, atrial
septostomy, and lung transplants as therapeutic approaches
for various pulmonary hypertension entities (8–12,35,39–41),
clinical trials since 2000 have demonstrated therapeutic effi-
cacy with prostaglandins and endothelin antagonists for pul-
monary arterial hypertension (37,42). Correct diagnosis of
the distinct disease entities of pulmonary hypertension pro-
vides direction for management of the underlying disease
(39,43) and is imperative to prevent a treatment regimen that
might worsen the condition or create serious sequelae (3).
Disease assessment includes physical examination, electrocar-
diogram, echocardiogram, chest radiograph, ventilation-per-
fusion scintigraphy, and other assessments (2,4,10,11,43).
Limitations develop as the symptoms become worse, particu-
larly for symptoms of other comorbid conditions. For example,
among patients with HIV, symptoms related to pulmonary
hypertension might overshadow the overall clinical problems
of these patients (44). In addition, pulmonary hypertension
might increase the risk for complications and death during
pregnancy (45–47).
Conclusion
The high proportion of pulmonary hypertension–related
deaths and hospitalizations that occurred among adults aged
>65 years suggested that as the proportion of older adults in
the U.S. population increases, pulmonary hypertension might
continue to be a more frequent diagnosis, particularly with
concomitant chronic heart failure. Because the majority of
patients with pulmonary hypertension are older adults, the
burden of chronic disability and morbidity on the Medicare
system and families will increase. Prevention efforts, includ-
ing broad-based public health efforts to increase awareness of
pulmonary hypertension and to foster appropriate diagnostic
evaluation and timely treatment from health-care providers,
should be considered. The science base for the etiology, patho-
genesis, and complications of pulmonary hypertension dis-
ease entities must be further investigated to improve
prevention, treatment, and case management. Additional
epidemiologic initiatives also are needed to ascertain the
prevalence and incidence of the various disease entities.
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Although multiple predisposing factors and associated con-
ditions have been identified for pulmonary hypertension, the
causal roles and strengths of association have not been well
established (38,48). Therefore, it is not possible to establish
preventive measures regarding risk factor reduction. However,
attention should be focused on the following key areas: iden-
tifying the initiation of disease, discovering a common link
between known and emerging causal factors, exploring
associations between suspected variables and the disease, and
identifying prevention efforts.
Acknowledgments
The authors acknowledge the comments, suggestions, and insights
provided by the scientific leadership of the Pulmonary Hypertension
Association.
References
1. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension:
a national prospective study. Annals Intern Med 1987;107:216–23.
2. National Heart, Lung, and Blood Institute. Primary pulmonary hy-
pertension. Bethesda, MD: US Department of Health and Human
Services; November 1996. NIH publication no. 96-3291.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet
1998;352:719–25.
4. Chatterjee K, De Marco T, Alpert JS. Pulmonary hypertension: hemo-
dynamic diagnosis and management. Archives Intern Med
2002;162:1925–33.
5. D’Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with pri-
mary pulmonary hypertension: results from a national prospective
registry. Annals Intern Med 1991;115:343–9.
6. Kawut SM, Horn EM, Berekashvili KK, et al. New predictors of out-
come in idiopathic pulmonary arterial hypertension. Am J Cardiol
2005;95:199–203.
7. Rubin LJ. ACCP consensus statement: primary pulmonary
hypertension. Chest 1993;104:236–50.
8. McLaughlin VV, Rich S. Pulmonary hypertension—advances in medical
and surgical interventions. J Heart Lung Transplant 1998;17:739–43.
9. Gaine SP, Rubin LJ. Medical and surgical treatment options for pul-
monary hypertension. Am J Med Sci 1998;315:179–84.
10. Krowka MJ. Pulmonary hypertension: diagnostics and therapeutics.
Mayo Clinic Proceedings 2000;75:625–30.
11. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of
pulmonary arterial hypertension: ACCP evidence-based clinical prac-
tice guidelines. Chest 2004;126(Suppl 1):78S–92S.
12. Peacock AJ. Treatment of pulmonary hypertension: several options exist,
but they are expensive and necessitate specialist care [Editorial]. Brit
Med J 2003;326:835–6.
13. Fishman AP. Primary pulmonary arterial hypertension: a look back.
J Am Coll Cardiol 2004;43:2S–4S.
14. Fishman AP. Clinical classification of pulmonary hypertension.
Clinics in Chest Med 2001;22:385–91.
15. Lilienfeld DE, Rubin LJ. Mortality from primary pulmonary hyper-
tension in the United States, 1979–1996. Chest 2000;117:796–800.
16. Rich S, Chomka E, Hasara L, et al. The prevalence of pulmonary
hypertension in the United States: adult population estimates obtained
from measurements of chest roentgenograms from the NHANES II
survey. Chest 1989;96:236–41.
17. World Health Organization. Manual of the international statistical
classification of diseases, injuries, and causes of death, 9th Revision,
Vol. 1. Geneva, Switzerland: World Health Organization; 1977.
18. World Health Organization. International statistical classification of
diseases and related health problems, 10th revision. Geneva,
Switzerland: World Health Organization; 1992.
19. Anderson RN, Minino AM, Hoyert DL, Rosenberg HM. Compara-
bility of cause of death between ICD-9 and ICD-10: preliminary esti-
mates. Natl Vital Stat Rep 2001;49(2).
20. National Center for Health Statistics. National Vital Statistics System.
Hyattsville, MD: US Department of Health and Human Services,
CDC, National Center for Health Statistics; 2002. Available at
http://www.cdc.gov/nchs/nvss.htm.
21. Anderson RN, Rosenberg HM. Age standardization of death rates:
implementation of the year 2000 standard. Natl Vital Stat Rep
1998;47(3).
22. Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected
US population. Healthy People 2010 Statistics Notes, No. 20.
Hyattsville, MD: US Department of Health and Human Services,
CDC, National Center for Health Statistics; 2001.
23. Mannino DM, Homa DM, Akinbami LJ, Ford ES, Redd SC. Chronic
obstructive pulmonary disease surveillance—United States, 1971–
2000. In: Surveillance Summaries, August 2, 2002. MMWR
2002;51(No. SS-6):1–16.
24. Simmons WR, Schnack GA. Development of the design of the NCHS
Hospital Discharge Survey. Vital Health Statistics, series 2, no. 39.
Rockville, MD: Human Resources Administration; 1977. DHEW
publication no. (HRA)77-1199. Available at http://www.cdc.gov/nchs/
data/series/sr_02/sr02_039.pdf.
25. Dennison CF, Pokras R. Design and operation of the National
Hospital Discharge Survey: 1988 redesign. Vital Health Stat
2000;1(39).
26. US Department of Health and Human Services. The International
Classification of Diseases, Ninth Revision, Clinical Modification.
4th ed. Hyattsville, MD: US Department of Health and Human Ser-
vices, CDC, National Center for Health Statistics, Health Care Fi-
nancing Administration; 1991. DHHS publication no. (PHS) 91-1260.
27. Kozak LJ. Underreporting of race in the National Hospital Discharge
Survey. Hyattsville, MD: US Department of Health and Human Ser-
vices, CDC, National Center for Health Statistics; 1995. Advance data
no. 265. Available at http://www.cdc.gov/nchs/data/ad/ad265.pdf.
28. Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs
and the risk of primary pulmonary hypertension. N Engl J Med
1996;335:609–61.
29. Abenhaim L, Humbert M. Pulmonary hypertension related to drugs
and toxins. Current Opinion in Cardiology 1999;14:437–41.
30. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens
and pulmonary hypertension in the United States: results from the
surveillance of North American pulmonary hypertension. Chest
2000;117:870–4.
31. Stafford RS, Radley DC. National trends in antiobesity medicare use.
Arch Intern Med 2003;163:1046–50.
Vol. 54 / SS-5 Surveillance Summaries 9
32. Khan LK, Serdula MK, Bowman BA, Williamson DF. Use of prescrip-
tion weight loss pills among U.S. adults in 1996–1998. Ann Intern
Med 2001;134:282–6.
33. Israel RA, Rosenberg HM, Curtin LR. Analytical potential for
multiple cause-of-death data. Am J Epidemiol 1986;124:161–79.
34. Rich S. Clinical insights into the pathogenesis of primary pulmonary
hypertension. Chest 1998;114:237S–241S.
35. Rubin LJ. Primary pulmonary hypertension. N Engl J Med
1997;336:111–7.
36. Archer S, Rich S. Primary pulmonary hypertension: a vascular biology
and translational “work in progress.” Circulation 2000;102:2781–91.
37. Hoepner MM, Galie N, Simonneau G, Rubin LJ. New treatments for
pulmonary arterial hypertension. Am J Respir Crit Care Med
2002;165:1209–16. 2004;43(Suppl):5S–12S.
38. Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pul-
monary hypertension. J Am Coll Cardiol 2004;43(Suppl):5S–12S.
39. Gaine S. Pulmonary hypertension. JAMA 2000;284:3160–8.
40. Barst RJ. Role of atrial septostomy in the treatment of pulmonary
vascular disease. Thorax 2000;55:95–6.
41. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical
modalities of treatment of pulmonary arterial hypertension. J Am Coll
Cardiol 2004;43(Suppl S):73S–80S.
42. Galie N, Seeger W, Naeije R, Simonneau G, Rubin LJ. Comparative
analysis of clinical trials and evidence-based treatment algorithm in
pulmonary arterial hypertension. J Am Coll Cardiol 2004;43
(Suppl S):81S–88S.
43. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential
assessment of pulmonary arterial hypertension. J Am Coll Cardiol
2004;43(Suppl S):40S–47S.
44. Recusani R, DiMatteo A, Gambarin F, D’Armini A, Klersy C, Campana
C. Clinical and therapeutical follow-up of HIV-associated pulmonary
hypertension: prospective study of 10 patients. AIDS 2003;17
(Suppl 1):S88–S95.
45. Kiss H, Egarter C, Asseryanis E, Putz D, Kneussl M. Primary pulmo-
nary hypertension in pregnancy: a case report. Am J Obstet Gynecol
1995;172:1052–4.
46. Easterling TR, Ralph DD, Schmucker BC. Pulmonary hypertension
in pregnancy: treatment with pulmonary vasodilators. Obstet Gynecol
1999;93:494–8.
47. Monnery L, Nanson J, Charlton G. Primary pulmonary hypertension
in pregnancy; a role for novel vasodilators. Br J Anaesth 2001;87:295–8.
48. Farber HW, Loscalzo J. Mechanisms of disease: pulmonary arterial
hypertension. N Engl J Med 2004;351:1655–65.
10 MMWR November 11, 2005
TABLE 1. Number of decedents with pulmonary hypertension* as any contributing cause of death and age-standardized death
rate,† by sex and year — United States, 1980–2002
Men Women Total
Year No. Rate No.  Rate  No. Rate
1980 6,999 8.2 3,923 3.3 10,922 5.2
1981 6,686 7.7 4,042 3.3 10,728 5.0
1982 6,306 7.2 3,910 3.2 10,216 4.7
1983 6,462 7.3 4,423 3.5 10,885 5.0
1984 6,655 7.4 4,673 3.7 11,328 5.1
1985 6,644 7.3 4,761 3.7 11,405 5.1
1986 6,350 6.9 4,946 3.8 11,296 5.0
1987 6,240 6.6 5,189 3.9 11,429 5.0
1988 6,302 6.6 5,386 4.0 11,688 5.0
1989 6,388 6.6 5,517 4.1 11,905 5.0
1990 6,391 6.5 5,689 4.1 12,080 5.0
1991 6,359 6.4 6,142 4.4 12,501 5.1
1992 6,317 6.2 6,417 4.5 12,734 5.2
1993 6,498 6.3 6,594 4.6 13,092 5.2
1994 6,206 5.9 6,766 4.6 12,972 5.1
1995 6,217 5.8 6,923 4.8 13,140 5.1
1996 6,317 5.9 7,186 4.8 13,503 5.2
1997 6,520 5.9 7,766 5.1 14,286 5.4
1998 6,431 5.8 8,042 5.2 14,473 5.4
1999 6,618 5.9 8,428 5.4 15,046 5.5
2000 6,273 5.5 8,629 5.4 14,902 5.4
2001 6,514 5.6 9,083 5.6 15,597 5.5
2002 6,484 5.4 9,184 5.5 15,668 5.4
* International Classification of Diseases, Ninth Revision codes 416.0, 416.8, or 416.9 during 1980–1998 and International Classification of Diseases, Tenth
Revision codes I27.0, I27.8, or I27.9 during 1999–2002.
† Per 100,000 population. Age-standardized to the 2000 U.S. standard population.
TABLE 2. Number of decedents with pulmonary hypertension* as any contributing cause of death and age-standardized death
rate,† by race and year — United States, 1980–2002
Asian/ American Indian/
White Black Pacific Islander Alaska Native
Year No. Rate No. Rate No. Rate  No. Rate
1980 9,901 5.3 929 4.6 45 § 33   §
1981 9,699 5.1 944 4.6 49 § 24   §
1982 9,142 4.7 966 4.6 65 § 25   §
1983 9,725 5.0 1,052 5.0 59 § 34   §
1984 10,124 5.1 1,078 5.0 56 § 35   §
1985 10,112 5.1 1,151 5.4 64 § 40   §
1986 9,895 4.9 1,272 5.8 73 § 35   §
1987 10,054 4.9 1,223 5.5 93 § 35   §
1988 10,274 4.9 1,259 5.6 83 § 32   §
1989 10,395 4.9 1,353 5.9 114 § 43   §
1990 10,613 5.0 1,317 5.7 111 2.4 39   ¶
1991 10,838 5.0 1,481 6.4 143 3.0 39   ¶
1992 11,064 5.0 1,496 6.3 133 2.6 41   ¶
1993 11,413 5.1 1,490 6.1 137 2.7 52   ¶
1994 11,198 5.0 1,572 6.3 141 2.5 61   ¶
1995 11,275 4.9 1,642 6.6 170 2.8 53   ¶
1996 11,619 5.0 1,660 6.6 164 2.4 60   ¶
1997 12,269 5.2 1,770 6.8 188 2.8 59   ¶
1998 12,408 5.2 1,815 6.9 190 2.7 60   ¶
1999 12,740 5.3 2,043 7.6 195 2.8 68   ¶
2000 12,682 5.2 1,952 7.2 200 2.5 68   ¶
2001 13,279 5.4 2,032 7.3 219 2.6 67   ¶
2002 13,335 5.3 2,061 7.3 203 2.2 69   ¶
* International Classification of Diseases, Ninth Revision codes 416.0, 416.8, or 416.9 during 1980–1998 and International Classification of Diseases, Tenth
Revision codes I27.0, I27.8, or I27.9 during 1999–2002.
† Per 100,000 population. Age-standardized to the 2000 U.S. standard population.
§ American Indian/Alaska Native and Asian/Pacific Islander categories did not exist in Census data before 1990.
¶ Numbers might be too small to calculate stable age-standardized death rates.
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TABLE 3. Number of decedents with pulmonary hypertension*
as any contributing cause of death and age-standardized death
rate,† by Hispanic origin and year — United States, 1990–2002
Hispanic Non-Hispanic
Year No. Rate No. Rate
1990 369 2.7 11,246 4.9
1991 419 3.3 11,806 5.1
1992 433 3.1 12,015 5.1
1993 401 2.9 12,486 5.2
1994 414 2.7 12,395 5.1
1995 471 3.1 12,490 5.1
1996 468 2.9 12,855 5.2
1997 538 3.2 13,697 5.5
1998 596 3.5 13,829 5.4
1999 552 3.0 14,447 5.6
2000 625 3.4 14,234 5.5
2001 645 3.2 14,916 5.6
2002 617 3.0 15,003 5.6
* International Classification of Diseases, Ninth Revision codes 416.0, 416.8,
or 416.9 during 1990–1998 and International Classification of Diseases,
Tenth Revision codes I27.0, I27.8, or I27.9 during 1999–2002.
†Per 100,000 population. Age-standardized to the 2000 U.S. standard
population.
TABLE 4. Number of decedents with pulmonary hypertension* as any contributing cause of death and age-specific death rate,†
by age group and year — United States, 1980–2002
0–44 yrs 45–54 yrs 55–64 yrs 65–74 yrs 75–84 yrs >85 yrs
Year No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
1980 1,085 0.7 708 3.1 2,146 9.9 3,782 24.2 2,496 32.1 705 31.0
1981 1,065 0.7 675 3.0 2,112 9.6 3,820 24.0 2,407 30.2 649 27.6
1982 1,049 0.7 578 2.6 1,951 8.9 3,546 22.0 2,394 29.2 695 28.5
1983 1,189 0.7 598 2.7 2,068 9.4 3,670 22.4 2,650 31.4 709 28.1
1984 1,284 0.8 596 2.7 2,018 9.1 3,813 22.9 2,841 32.8 776 29.9
1985 1,294 0.8 629 2.8 2,020 9.1 3,693 21.9 2,908 32.7 860 32.2
1986 1,321 0.8 592 2.6 1,907 8.7 3,702 21.6 2,953 32.3 818 29.8
1987 1,325 0.8 600 2.6 1,893 8.7 3,648 20.9 3,101 33.1 860 30.5
1988 1,330 0.8 640 2.7 1,915 8.9 3,810 21.6 3,103 32.3 890 30.8
1989 1,471 0.9 626 2.5 1,884 8.9 3,731 20.9 3,271 33.2 921 31.0
1990 1,461 0.8 592 2.3 1,807 8.6 3,812 21.1 3,393 33.7 1,015 33.2
1991 1,465 0.8 653 2.5 1,724 8.2 3,849 21.1 3,662 35.5 1,147 36.0
1992 1,483 0.9 702 2.6 1,766 8.4 3,854 20.9 3,719 35.3 1,210 36.5
1993 1,460 0.8 666 2.3 1,784 8.5 3,897 20.9 3,965 36.9 1,320 38.3
1994 1,469 0.8 708 2.4 1,685 8.0 4,006 21.4 3,766 34.4 1,338 37.6
1995 1,584 0.9 773 2.5 1,710 8.1 3,662 19.5 3,894 34.8 1,517 41.2
1996 1,425 0.8 868 2.7 1,632 7.6 3,725 19.9 4,131 36.0 1,720 45.3
1997 1,611 0.9 919 2.7 1,724 7.9 3,744 20.2 4,348 37.0 1,939 49.5
1998 1,611 0.9 974 2.8 1,699 7.5 3,726 20.3 4,346 36.4 2,117 52.2
1999 1,630 0.9 1,014 2.8 1,779 7.6 3,677 20.2 4,519 37.2 2,427 58.1
2000 1,535 0.8 1,047 2.8 1,726 7.1 3,511 19.1 4,522 36.6 2,561 60.4
2001 1,635 0.9 1,081 2.8 1,793 7.1 3,503 19.1 4,755 37.8 2,829 64.2
2002 1,555 0.8 1,122 2.8 1,848 6.9 3,343 18.3 4,830 37.9 2,969 64.6
* International Classification of Diseases, Ninth Revision codes 416.0, 416.8, or 416.9 during 1980–1998 and International Classification of Diseases, Tenth
Revision codes I27.0, I27.8, or I27.9 during 1999–2002.
†Per 100,000 population.
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TABLE 5. Age-standardized and age-specific death rates* for pulmonary hypertension† as any contributing cause of death for
groups defined by selected characteristics, by period — United States, 1980–2002
Characteristic 1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
Age-standardized§ death rate
Total 5.0 5.0 5.1 5.3 5.4
Men 7.5 6.8 6.3 5.9 5.5
Women 3.4 3.9 4.5 5.1 5.5
Race
White 5.0 4.9 5.0 5.1 5.3
Black 4.8 5.6 6.2 6.9 7.3
Asian/Pacific Islander ¶ ¶ 2.6 2.7 2.4
American Indian/Alaska Native ¶ ¶ ** ** **
Hispanic origin
Hispanic ¶ ¶ 2.9 3.1 3.2
Non-Hispanic ¶ ¶ 5.1 5.4 5.6
Age-specific death rate
Total
0–44 yrs 0.7 0.8 0.8 0.9 0.9
45–54 yrs 2.8 2.6 2.4 2.7 2.8
55–64 yrs 9.4 8.9 8.4 7.7 7.0
65–74 yrs 23.1 21.4 21.1 20.0 18.8
75–84 yrs 31.1 32.7 35.2 36.3 37.4
>85 yrs 29.0 30.9 36.4 49.5 63.2
Men
0–44 yrs 0.7 0.8 0.8 0.8 0.8
45–54 yrs 2.9 2.7 2.2 2.4 2.4
55–64 yrs 12.0 10.3 8.9 7.6 6.4
65–74 yrs 34.7 28.3 25.3 21.6 19.0
75–84 yrs 56.1 51.3 48.3 43.1 39.7
>85 yrs 55.7 53.6 55.0 62.7 68.9
Women
0–44 yrs 0.7 0.8 0.9 1.0 0.9
45–54 yrs 2.7 2.6 2.6 3.0 3.1
55–64 yrs 7.1 7.6 7.9 7.8 7.6
65–74 yrs 14.2 16.0 17.8 18.7 18.7
75–84 yrs 16.5 21.7 27.1 31.9 36.0
>85 yrs 17.9 21.9 29.2 44.1 60.7
White
0–44 yrs 0.6 0.7 0.7 0.7 0.7
45–54 yrs 2.6 2.4 2.1 2.3 2.4
55–64 yrs 9.3 8.7 8.1 7.2 6.6
65–74 yrs 23.8 21.7 21.1 19.8 18.6
75–84 yrs 32.2 33.5 35.8 36.6 37.9
>85 yrs 30.0 31.3 37.0 50.5 64.1
Black
0–44 yrs 1.3 1.6 1.6 1.7 1.7
45–54 yrs 4.8 5.3 5.4 6.2 6.2
55–64 yrs 11.2 11.8 11.4 12.8 12.5
65–74 yrs 17.4 20.5 23.5 23.8 25.2
75–84 yrs 20.1 25.4 30.6 35.6 38.7
>85 yrs 17.5 25.9 29.9 43.6 56.1
* Per 100,000 population.
† International Classification of Diseases, Ninth Revision codes 416.0, 416.8, or 416.9 for deaths during 1980–1998 and International Classification of
Diseases, Tenth Revision codes I27.0, I27.8, or I27.9 for deaths during 1999–2002.
§ To the 2000 U.S. standard population.
¶ Hispanic origin and American Indian/Alaska Native and Asian/Pacific Islander race categories did not exist in Census data before 1990.
** Numbers might be too small to calculate stable age-standardized death rates.
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TABLE 6. Annual number of decedents with pulmonary hypertension* as any contributing cause of death, aggregated number,
and age-standardized death rate,† by state/area — United States, 2000–2002
2000 2001 2002 2000–2002
State/Area No. No. No. No. Rate
Alabama 224 233 229 686 5.0
Alaska 26 22 30 78 7.7§
Arizona 192 229 216 637 4.0
Arkansas 103 99 105 307 3.6
California 1,432 1,488 1,423 4,343 4.8
Colorado 284 323 322 929 8.6
Connecticut 184 175 155 514 4.5
Delaware 48 65 53 166 6.8
District of Columbia 53 53 44 150 8.8
Florida 888 898 958 2,744 4.4
Georgia 335 375 312 1,022 4.9
Hawaii 52 51 60 163 4.3
Idaho 100 115 109 324 8.9
Illinois 646 666 688 2,000 5.5
Indiana 372 371 356 1,099 6.0
Iowa 196 225 216 637 6.1
Kansas 147 178 189 514 6.0
Kentucky 259 226 235 720 5.9
Louisiana 163 180 186 529 4.2
Maine 100 95 85 280 6.3
Maryland 312 298 293 903 6.0
Massachusetts 274 254 290 818 4.0
Michigan 593 565 609 1,767 6.0
Minnesota 302 303 385 990 6.6
Mississippi 123 153 141 417 5.0
Missouri 380 387 370 1137 6.3
Montana 59 87 72 218 7.4
Nebraska 99 104 102 305 5.4
Nevada 75 82 88 245 4.5
New Hampshire 87 97 80 264 7.2
New Jersey 392 385 391 1,168 4.4
New Mexico 104 114 135 353 6.8
New York 795 830 855 2,480 4.2
North Carolina 555 617 579 1,751 7.4
North Dakota 37 38 40 115 5.2
Ohio 853 908 896 2,657 7.4
Oklahoma 186 170 189 545 5.0
Oregon 219 230 243 692 6.4
Pennsylvania 844 876 854 2,574 5.8
Rhode Island 54 66 63 183 5.0
South Carolina 194 232 234 660 5.6
South Dakota 39 45 44 128 4.9
Tennessee 303 307 356 966 5.6
Texas 863 924 936 2,723 5.1
Utah 87 121 121 329 6.6
Vermont 46 53 62 161 8.4
Virginia 416 361 410 1,187 6.0
Washington 325 369 359 1,053 6.3
West Virginia 152 155 151 458 7.3
Wisconsin 288 345 304 937 5.5
Wyoming 42 54 45 141 9.9
Total 14,902 15,597 15,668 46,167 5.4
* International Classification of Diseases, Tenth Revision codes I27.0, I27.8, or I27.9 reported as any contributing cause of death on the death certificate
†Per 100,000 population. Age-standardized to the 2000 U.S. standard population.
§Number of deaths might be too small to calculate a stable age-standardized death rate.
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TABLE 7. Percentage of selected characteristics among decedents with pulmonary hypertension* reported as any contributing
cause of death, by period — United States, 1980–2002
1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
Characteristic (N = 54,079) (N = 57,723) (N = 63,379) (N = 70,448) (N = 46,167)
Women 38.8% 44.7% 49.9% 54.4% 58.3%
Race
White 89.9% 87.9% 87.0% 85.6% 85.1%
Black 9.2% 10.8% 11.6% 12.7% 13.1%
Other race/missing race 0.9% 1.3% 1.4% 1.7% 1.8%
Hispanic origin † † 3.2% 3.7% 4.1%
Age group (yrs)
0–44 10.5% 11.7% 11.6% 11.2% 10.2%
45–54 5.8% 5.3% 5.2% 6.5% 7.0%
55–64 19.0% 16.7% 13.8% 12.1% 11.6%
65–74 34.5% 32.2% 30.6% 26.3% 22.4%
75–84 23.7% 26.6% 29.2% 30.1% 30.6%
>85 6.5% 7.5% 9.5% 13.8% 18.1%
* International Classification of Diseases, Ninth Revision codes 416.0, 416.8, or 416.9 for deaths during 1980–1998 and International Classification of
Diseases, Tenth Revision codes I27.0, I27.8, or I27.9 for deaths during 1999–2002.
† Information on Hispanic origin not available.
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TABLE 8. Percentage of selected causes of death reported as the underlying cause of death among all decedents with pulmonary
hypertension reported as any contributing cause of death, by period — United States, 1980–2002
Underlying cause of death reported 1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
on death certificate (ICD-9/ICD-10 codes*) (N = 54,079) (N = 57,723) (N = 63,379) (N = 70,448) (N = 46,167)
Pulmonary hypertension (416.0, 14.3% 17.6% 19.3% 23.5% 30.3%
416.8, 416.9/I27.0, I27.8, I27.9)
Chronic lower respiratory diseases 49.2% 44.5% 40.8% 33.8% 25.9%
(490–494, 496/J40–J47)
Coronary heart disease (410–414, 8.4% 7.9% 7.6% 8.2% 8.6%
429.2/I20–I25)
All other cardiovascular diseases 5.2% 5.9% 6.6% 7.3% 7.2%
(390–405, 415, 416.1, 417, 420–423,
425–427, 429.0, 429.1, 429.3–429.9,
430–434, 436–448/I00–I19, I26,
I27.1, I28–I34, I40–I49, I51–I78)
All other respiratory diseases (460–478, 495, 6.6% 6.0% 6.0% 5.8% 5.9%
500–519/J00–J06, J20–J22, J60–J99)
Congenital malformations, 2.9% 3.2% 3.4% 3.3% 2.9%
deformations, and chromosomal
abnormalities (740–759/Q00–Q99)
Chronic valvular heart disease 0.5% 0.7% 1.3% 2.1% 2.8%
(424/I35–I39)
Malignant neoplasms of trachea, 2.0% 2.0% 2.2% 2.0% 1.7%
bronchus, and lung (162/C33–C44)
Systemic lupus erythematosus (710.0/M32), 0.8% 1.2% 1.7% 2.2% 1.2%
 systemic sclerosis (710.1/M34),
 dermatomyositis (710.3–710.4/M33),
 sicca syndrome (710.2/M35),
 rheumatoid arthritis (714.0–714.2/M05–M06), and
 juvenile arthritis (714.3/M08–M09)
Complications of pregnancy, childbirth, and the 1.8% 2.3% 1.5% 1.2% 1.1%
puerperium (640–676/O10–O99), or conditions
originating in the perinatal period
(760–771.2, 771.4–779/P00–P96)
Influenza and pneumonia (480–487/J10–J18) 1.4% 1.5% 1.4% 1.3% 1.0%
Heart failure (428/I50) 0.7% 0.8% 0.8% 0.9% 0.7%
Chronic liver disease and cirrhosis 0.2% 0.3% 0.3% 0.3% 0.3%
(571/K70, K73–K74)
Human immunodeficiency virus infection 0 0 0.1% 0.1% 0.1%
(042–044/B20–B24)
All other causes 6.0% 6.1% 7.0% 8.1% 10.2%
* International Classification of Diseases, Ninth Revision (ICD-9) codes 416.0, 416.8, or 416.9 for deaths during 1980–1998 and International Classification
of Diseases, Tenth Revision (ICD-10) codes I27.0, I27.8, or I27.9 for deaths during 1999–2002.
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TABLE 9. Percentage of selected causes of death reported as the underlying cause of death among decedents aged <45 years
with pulmonary hypertension reported as any contributing cause of death, by period — United States, 1980–2002
Underlying cause of death reported 1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
on death certificate (ICD-9/ICD-10 codes*) (N = 5,672) (N = 6,741) (N = 7,338) (N = 7,861) (N = 4,725)
Pulmonary hypertension (416.0, 29.8% 32.7% 36.4% 39.1% 39.8%
416.8, 416.9/I27.0, I27.8, I27.9)
Congenital malformations, 20.9% 21.4% 23.0% 22.3% 21.7%
deformations, and chromosomal
abnormalities (740–759/Q00–Q99)
Complications of pregnancy, childbirth, and the 17.3% 19.6% 12.8% 10.3% 10.5%
puerperium (640–676/O10–O99), or conditions
originating in the perinatal period
(760–771.2, 771.4–779/P00–P96)




All other respiratory diseases (460–478, 495, 4.1% 3.5% 3.4% 3.4% 4.2%
 500–519/J00–J06, J20–J22, J60–J99)
Chronic lower respiratory diseases 5.2% 3.2% 2.6% 2.5% 2.7%
(490–494, 496/J40–J47)
Systemic lupus erythematosus (710.0/M32), 2.1% 2.7% 3.6% 3.7% 2.4%
 systemic sclerosis (710.1/M34),
 dermatomyositis (710.3–710.4/M33),
 sicca syndrome (710.2/M35),
 rheumatoid arthritis (714.0–714.2/M05–M06), and
 juvenile arthritis (714.3/M08–M09)
Influenza and pneumonia (480–487/J10–J18) 1.1% 1.0% 0.9% 1.0% 0.6%
All other causes 14.1% 10.3% 11.0% 10.9% 11.9%
* International Classification of Diseases, Ninth Revision (ICD-9) codes 416.0, 416.8, or 416.9 for deaths during 1980–1998 and International Classification
of Diseases, Tenth Revision (ICD–10) codes I27.0, I27.8, or I27.9 for deaths during 1999–2002.
TABLE 10. Estimated annual number of hospitalizations and age-standardized hospital rate* for persons with pulmonary
hypertension† as any-listed diagnosis during hospital stay, by year and sex — National Hospital Discharge Survey, United States,
1980–2002
Men Women Total
Year No. Rate No. Rate No. Rate
1980 47,000 52.0 40,000 33.5 87,000 40.8
1981 51,000 55.5 34,000 28.0 85,000 39.1
1982 62,000 67.2 39,000 31.9 101,000 46.1
1983 58,000 61.8 45,000 35.8 103,000 46.1
1984 67,000 68.1 56,000 45.0 123,000 54.5
1985 57,000 57.8 54,000 41.6 111,000 48.1
1986 60,000 61.7 60,000 46.9 120,000 52.1
1987 59,000 58.4 49,000 37.5 108,000 45.9
1988 56,000 54.4 58,000 43.8 114,000 47.8
1989 56,000 52.4 53,000 40.7 109,000 45.5
1990 55,000 53.0 61,000 45.1 116,000 48.4
1991 69,000 64.1 71,000 53.9 140,000 58.5
1992 68,000 62.6 83,000 60.6 151,000 61.6
1993 67,000 62.6 87,000 61.8 154,000 61.9
1994 79,000 75.8 84,000 58.1 163,000 64.9
1995 83,000 77.4 101,000 69.8 184,000 71.9
1996 76,000 68.9 111,000 76.2 187,000 72.7
1997 86,000 76.6 120,000 80.9 206,000 78.6
1998 105,000 92.3 146,000 97.5 251,000 94.4
1999 110,000 95.5 146,000 94.8 256,000 94.6
2000 113,000 97.6 172,000 110.1 285,000 104.1
2001 102,000 84.3 160,000 99.2 262,000 92.7
2002 103,000 82.3 157,000 95.3 260,000 90.1
* Per 100,000 population. Age-standardized to the 2000 U.S. standard population.
† International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for hospital diagnoses during 1980–2002.
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TABLE 11. Estimated annual number* of hospitalizations and age-specific hospital rate† for persons with pulmonary hypertension§
as any-listed diagnosis during hospital stay, by year and age group — National Hospital Discharge Survey, United States, 1980–
2002
0–44 yrs 45–54 yrs 55–64 yrs 65–74 yrs 75–84 yrs >85 yrs
Year No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate
1980 10,000 6.4 8,000 33.1 20,000 94.2 31,000 198.4 15,000 191.9 3,000 146.9
1981 11,000 6.9 5,000 25.1 21,000 95.8 30,000 189.3 15,000 188.8 3,000 122.6
1982 13,000 8.2 10,000 43.0 24,000 109.9 33,000 205.9 18,000 226.1 3,000 106.4
1983 10,000 6.3 7,000 29.2 28,000 127.2 34,000 209.5 21,000 251.4 3,000 117.5
1984 14,000 8.8 11,000 49.4 31,000 138.2 41,000 245.4 22,000 253.0 4,000 159.5
1985 12,000 7.4 7,000 32.8 27,000 121.6 42,000 247.1 18,000 201.5 5,000 184.6
1986 17,000 10.0 10,000 42.8 22,000 100.7 41,000 241.2 26,000 281.9 4,000 156.0
1987 12,000 7.2 5,000 23.0 24,000 111.1 38,000 218.5 24,000 256.4 4,000 156.9
1988 17,000 10.5 7,000 29.5 28,000 128.4 37,000 211.4 19,000 196.4 5,000 193.5
1989 21,000 12.4 10,000 39.6 21,000 98.0 33,000 183.8 20,000 208.3 4,000 131.8
1990 14,000 8.1 12,000 47.2 20,000 97.3 42,000 235.1 23,000 234.0 4,000 146.4
1991 17,000 9.4 19,000 72.5 26,000 124.9 43,000 240.6 28,000 274.0 7,000 227.3
1992 18,000 10.2 14,000 50.6 26,000 125.4 47,000 259.6 37,000 357.3 8,000 261.6
1993 17,000 9.3 13,000 46.0 25,000 119.9 49,000 263.8 40,000 377.9 10,000 312.6
1994 14,000 7.5 13,000 43.7 22,000 107.2 52,000 283.1 46,000 424.9 16,000 450.1
1995 21,000 11.8 17,000 54.7 24,000 112.7 56,000 302.0 47,000 421.9 19,000 527.1
1996 20,000 10.8 20,000 62.2 28,000 133.5 51,000 276.5 49,000 436.8 19,000 503.3
1997 22,000 11.9 21,000 62.9 28,000 129.0 53,000 288.9 63,000 543.7 19,000 491.8
1998 21,000 11.4 24,000 69.1 43,000 192.0 67,000 369.3 69,000 580.8 27,000 676.2
1999 22,000 12.2 21,000 58.1 37,000 161.2 71,000 394.6 73,000 608.0 31,000 740.6
2000 22,000 12.3 23,000 60.6 38,000 160.1 72,000 400.9 87,000 713.7 43,000 997.6
2001 25,000 13.7 23,000 57.7 47,000 187.5 57,000 312.9 75,000 595.8 35,000 793.9
2002 28,000 15.2 24,000 58.7 45,000 169.4 58,000 315.8 65,000 512.1 40,000 880.3
* Estimated annual numbers for each age group are rounded to the nearest thousand; the sum of these numbers might not equal the total estimated annual
number of hospitalizations in Table 10.
†Per 100,000 population.
§ International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for hospital diagnoses during 1980–2002.
18 MMWR November 11, 2005
TABLE 13. Percentage of persons with selected characteristics hospitalized with pulmonary hypertension* as any-listed diagnosis,
by period — United States, 1980–2002
1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
Characteristic (N = 500,000) (N = 561,000) (N = 725,000) (N = 1,083,000) (N = 807,000)
Women 42.6% 48.9% 53.2% 57.6% 60.6%
Age group (yrs)
0–44 11.6% 14.1% 10.9% 9.7% 9.4%
45–54 8.1% 7.0% 9.8% 9.5% 8.5%
55–64 24.9% 21.7% 16.5% 14.8% 16.2%
65–74 33.9% 34.1% 32.3% 27.6% 23.2%
75–84 18.3% 19.1% 24.2% 27.8% 28.2%
>85 3.2% 4.1% 6.4% 10.6% 14.6%
* International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for hospital diagnoses during 1980–2002.
TABLE 12. Estimated age-standardized and age-specific hospital rates* for groups with pulmonary hypertension† as any-listed
diagnosis, by selected characteristics and period — National Hospital Discharge Survey, United States, 1980–2002
Characteristic 1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
Age-standardized§ hospital rate
Total 45.4 47.8 59.2 82.7 95.5
Men 61.0 56.9 63.9 82.4 87.9
Women 34.9 42.1 56.0 84.0 101.5
Age-specific hospital rate
Total
0–44 yrs 7.3 9.5 8.9 11.6 13.7
45–54 yrs 35.9 33.6 51.6 61.5 59.0
55–64 yrs 113.2 112.0 114.9 146.5 172.5
65–74 yrs 210.1 220.0 256.7 325.9 342.9
75–84 yrs 223.2 228.5 335.6 520.5 605.8
>85 yrs 130.7 164.2 284.6 592.3 889.3
Men
0–44 yrs 5.9 8.6 9.2 9.0 12.5
45–54 yrs 34.7 29.9 46.3 58.2 52.9
55–64 yrs 139.3 127.8 118.8 149.1 154.5
65–74 yrs 311.1 277.5 291.5 328.7 308.4
75–84 yrs 378.4 308.4 389.0 507.4 600.8
>85 yrs 182.5 257.8 294.8 723.1 766.2
Women
0–44 yrs 8.8 10.5 8.6 14.3 15.0
45–54 yrs 37.1 37.0 56.7 64.6 64.8
55–64 yrs 90.1 98.0 111.4 144.2 189.2
65–74 yrs 132.6 175.3 229.1 323.5 371.6
75–84 yrs 131.9 181.3 302.7 529.2 609.0
>85 yrs 109.1 127.3 280.7 538.8 942.1
* Per 100,000 population.
† International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for hospital diagnoses during 1980–2002.
§ To the 2000 U.S. standard population.
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TABLE 14. Percentage of selected diseases reported as the principal (i.e., first-listed) diagnosis on hospital records with pulmonary
hypertension reported as any-listed diagnosis, by period — United States, 1980–2002
Principal diagnosis reported on hospital 1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
record  (ICD-9-CM codes*) (N = 500,000) (N = 561,000) (N = 725,000) (N = 1,083,000) (N = 807,000)
Heart failure (428) 5.9% 11.4% 14.6% 17.7% 18.7%
All other cardiovascular diseases (390–405, 6.8% 9.6% 11.8% 14.9% 16.3%
415, 416.1,420–423,425–427,429.0,
429.1,429.3–429.9,430–434, 436–448)
Chronic lower respiratory diseases (490–494, 496) 42.0% 23.1% 16.4% 13.4% 12.9%
Coronary heart disease (410–414, 429.2) 3.2% 5.0% 7.9% 9.2% 8.6%
Influenza and pneumonia (480–487) 4.5% 8.0% 7.7% 6.5% 8.4%
All other respiratory diseases (460–478, 495, 6.7% 13.3% 11.2% 9.2% 6.5%
500–519)
Pulmonary hypertension (416.0, 416.8, 416.9) 12.8% 10.7% 6.9% 5.3% 4.2%
Chronic valvular heart disease (424) 1.0% 1.3% 1.9% 2.3% 1.9%
Congenital malformations, deformations, and 3.0% 2.6% 2.9% 1.4% 0.7%
chromosomal abnormalities (740–759)
Chronic liver disease and cirrhosis (571) 0.2% 0.1% 0.2% 0.5% 0.5%
Complications of pregnancy, childbirth, and the 0.7% 1.8% 1.3% 0.2% 0.3%
puerperium (640–676), or conditions originating
in the perinatal period (760–771.2, 771.4–779)
Malignant neoplasms of trachea, bronchus, 0.7% 0.4% 0.4% 0.6% 0.2%
and lung (162)




rheumatoid arthritis (714.0–714.2), and
juvenile arthritis (714.3)
Human immunodeficiency virus infection (042–044) 0 0 0 0.1% 0
All other causes 11.8% 12.6% 16.2% 18.7% 20.7%
*International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for hospital diagnoses during 1980–2002.
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TABLE 15. Percentage of selected diseases reported as the principal (i.e., first-listed) diagnosis on hospital records of persons
aged <45 years with pulmonary hypertension as any-listed diagnosis, by period — United States, 1980–2002
Principal diagnosis reported on the 1980–1984 1985–1989 1990–1994 1995–1999 2000–2002
hospital record (ICD-9-CM codes*) (N = 58,000) (N = 79,000) (N = 79,000) (N = 105,000) (N = 76,000)
All other cardiovascular diseases, 13.9% 16.6% 19.9% 28.3% 29.8%
excluding pulmonary hypertension
(390–415, 416.1, 419–448)
All other respiratory diseases (460–478, 3.5% 11.2% 10.0% 9.0% 9.8%
495, 500–519)
Pulmonary hypertension (416.0, 416.8, 416.9) 26.0% 15.9% 9.7% 9.5% 9.5%
Chronic lower respiratory diseases 5.2% 4.6% 3.7% 4.3% 7.1%
(490–494, 496)
Influenza and pneumonia (480–487) 3.5% 6.4% 7.4% 7.2% 4.6%
Congenital malformations, 22.9% 16.1% 23.6% 12.7% 4.3%
deformations, and chromosomal
abnormalities (740–759)
Complications peculiar to certain 0.3% 2.2% 0.9% 2.2% 3.9%
specific procedures (996)
Cellulitis and abscess (681–682) 0 0 0.1% 1.0% 3.6%
Complications of pregnancy, childbirth, 5.9% 12.2% 11.8% 2.4% 3.2%
and the puerperium (640–676), or
conditions originating in the perinatal
period (760–771.2, 771.4–779)




rheumatoid arthritis (714.0–714.2), and
juvenile arthritis (714.3)
All other causes 15.7% 14.1% 12.6% 22.3% 23.5%
* International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for any-listed hospital diagnoses during 1980–2002.
TABLE 16. Annual number of Medicare hospitalizations and age-standardized hospital rate* for Medicare enrollees aged >65
years with pulmonary hypertension† as any-listed diagnosis during hospital stay, by sex and year — United States, 1990–2002
Men Women Total
Year No. Rate No. Rate No. Rate
1990 26,875 244.4 28,641 169.7 55,516 197.8
1991 29,229 262.5 32,959 192.5 62,188 218.8
1992 38,030 338.7 44,330 256.2 82,360 287.1
1993 43,142 381.4 51,977 298.0 95,119 329.3
1994 50,600 446.8 62,703 359.5 113,303 392.4
1995 55,575 493.9 72,318 417.3 127,893 446.1
1996 60,946 549.7 83,055 486.5 144,001 510.3
1997 67,405 625.0 95,125 569.1 162,530 589.8
1998 69,454 658.9 102,081 624.9 171,535 636.8
1999 72,028 686.9 108,667 671.0 180,695 675.8
2000 73,292 684.1 115,824 706.8 189,116 696.3
2001 69,300 622.3 112,074 666.8 181,374 648.1
2002 70,123 607.4 117,082 679.4 187,205 649.7
* Per 100,000 Medicare enrollees. Age-standardized to 2000 U.S. standard population aged >65 years.
† International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for any-listed diagnosis on Medicare hospital
claims during 1990–2002.
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TABLE 17. Annual number of Medicare hospitalizations and age-standardized hospital rate* for Medicare enrollees aged >65
years with pulmonary hypertension† as any-listed diagnosis during hospital stay, by race and year — United States, 1990–2002
White Black Asian Hispanic American Indian
Year No. Rate No. Rate No. Rate No. Rate No. Rate
1990 48,610 198.1 4,381 210.2 § § § § § §
1991 54,278 219.5 4,951 233.0 § § § § § §
1992 71,498 287.5 6,625 309.1 § § § § § §
1993 82,316 329.7 7,840 363.3 § § § § § §
1994 99,765 389.0 10,112 445.7 119 —¶ 346 —¶ 36 —¶
1995 112,856 445.1 11,688 523.2 276 —¶ 732 —¶ 96 —¶
1996 126,480 507.4 13,413 613.6 336 —¶ 906 —¶ 121 —¶
1997 142,504 587.4 15,235 717.3 536 —¶ 1,540 329.9 160 —¶
1998 149,908 633.1 16,459 796.8 729 —¶ 1,992 439.8 198 —¶
1999 157,691 671.8 17,138 838.6 809 —¶ 2,197 495.3 215 —¶
2000 164,692 687.8 18,293 868.6 765 —¶ 2,294 471.6 219 —¶
2001 157,857 641.0 17,703 808.9 909 —¶ 2,077 403.8 250 —¶
2002 162,179 641.2 18,572 823.0 982 —¶ 2,352 437.2 503 —¶
* Per 100,000 Medicare enrollees. Age-standardized to 2000 U.S. standard population aged >65 years.
† International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for any-listed diagnosis on Medicare hospital
claims during 1990–2002.
§ Information was not available for specific race or ethnic groups other than white or black.
¶ Number of hospitalizations might be too small to calculate stable age-standardized hospital rate.
TABLE 18. Annual number of Medicare hospitalizations and age-specific hospital rate* for Medicare enrollees aged >65 years
with pulmonary hypertension† as any-listed diagnosis during hospital stay, by year and age group — United States, 1990–2002
65–74 yrs 75–84 yrs >85 yrs
Year No. Rate No. Rate No. Rate
1990 30,296 187.8 20,635 228.0 4,585 151.4
1991 32,713 201.0 23,622 255.2 5,853 187.8
1992 41,642 254.1 32,040 341.4 8,678 270.3
1993 46,294 282.1 37,973 399.1 10,852 328.6
1994 53,706 329.3 45,475 475.7 14,122 420.8
1995 58,161 364.0 51,959 540.6 17,773 522.4
1996 62,295 403.7 59,666 620.9 22,040 644.0
1997 64,683 438.7 68,855 722.2 28,992 846.6
1998 64,944 460.6 74,160 788.0 32,431 943.7
1999 65,374 476.1 78,312 830.6 37,009 1,067.9
2000 65,862 474.8 82,355 858.1 40,899 1,157.4
2001 62,955 440.1 78,294 791.1 40,125 1,106.8
2002 63,557 431.9 80,763 791.1 42,885 1,154.2
* Per 100,000 Medicare enrollees.
† International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for any-listed diagnosis on Medicare hospital
claims during 1990–2002.
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TABLE 19. Age-standardized and age-specific Medicare hospital rates* for pulmonary hypertension† as any-listed diagnosis for
groups defined by selected characteristics, by period — United States, 1990–2002
Characteristic 1990–1994 1995–1999 2000–2002
Age-standardized§ hospital rate
Total 286.2 570.3 664.2
Men 336.2 602.2 637.0
Women 256.1 551.7 684.1
Race
White 286.1 567.3 656.3
Black 314.8 694.4 832.9
Asian ¶ 314.8 281.1
Hispanic ¶ 407.3 437.2
American Indian ¶ 592.4 612.2
Age-specific hospital rate
Total
65–74 yrs 251.1 426.4 448.5
75–84 yrs 341.6 699.6 812.7
>85 yrs 275.3 806.0 1,139.4
Men
65–74 yrs 274.6 433.4 419.7
75–84 yrs 415.2 751.9 791.5
>85 yrs 356.6 923.8 1,190.3
Women
65–74 yrs 232.3 420.6 473.1
75–84 yrs 297.1 666.7 826.6
>85 yrs 245.0 761.7 1,119.2
White
65–74 yrs 250.6 418.8 430.4
75–84 yrs 341.9 700.0 811.0
>85 yrs 275.3 814.1 1,157.1
Black
65–74 yrs 287.2 594.4 665.1
75–84 yrs 360.7 796.8 976.2
>85 yrs 303.0 821.8 1,117.4
* Per 100,000 Medicare enrollees.
† International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for any-listed diagnosis on Medicare hospital
claims during 1990–2002.
§ To 2000 U.S. standard population aged >65 years.
¶ Information was not available for specific race or ethnic populations other than white or black.
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TABLE 20. Annual number of Medicare hospitalizations with pulmonary hypertension* as any-listed diagnosis, aggregated number,
and age-standardized hospital rate,† by state/area — United States, 2000–2002
2000 2001 2002 2000–2002
State/Area No. No. No. No. Rate
Alabama 3,859 3,452 3,582 10,893 720.9
Alaska 209 191 243 643 659.9
Arizona 1,974 2,066 2,368 6,408 554.1
Arkansas 1,373 1,425 1,507 4,305 417.0
California 9,086 8,839 9,465 27,390 474.9
Colorado 2,703 2,610 2,679 7,992 1,022.8
Connecticut 1,856 1,898 2,067 5,821 484.4
Delaware 686 812 708 2,206 781.7
District of Columbia 508 447 407 1,362 782.0
Florida 14,688 13,378 14,185 42,251 732.1
Georgia 4,631 4,414 4,590 13,635 648.7
Hawaii 202 207 206 615 218.9
Idaho 1,121 1,036 974 3,131 796.3
Illinois 9,902 9,960 10,123 29,985 773.9
Indiana 5,610 5,040 5,203 15,853 748.5
Iowa 2,982 2,790 2,823 8,595 686.8
Kansas 1,929 1,791 2,052 5,772 594.3
Kentucky 3,334 3,173 3,119 9,626 703.1
Louisiana 2,726 2,484 2,691 7,901 638.4
Maine 1,172 1,043 1,145 3,360 626.0
Maryland 4,237 4,649 4,578 13,464 841.1
Massachusetts 3,694 3,653 3,863 11,210 591.8
Michigan 7,606 7,390 8,030 23,026 671.0
Minnesota 3,634 3,378 3,304 10,316 690.9
Mississippi 2,024 1,793 1,980 5,797 599.9
Missouri 4,312 4,384 4,470 13,166 713.5
Montana 998 998 975 2,971  833.2
Nebraska 1,586 1,410 1,522 4,518 685.4
Nevada 761 759 896 2,416 593.4
New Hampshire 1,093 1,077 1,092 3,262 747.6
New Jersey 6,193 5,844 6,476 18,513 661.2
New Mexico 1,206 1,257 1,310 3,773 792.5
New York 10,956 11,081 11,102 33,139 610.8
North Carolina 7,005 6,662 6,535 20,202 756.3
North Dakota 580 498 457 1,535 549.8
Ohio 9,802 8,743 8,855 27,400 745.4
Oklahoma 1,966 2,074 2,055 6,095 521.3
Oregon 1,433 1,563 1,636 4,632 582.7
Pennsylvania 13,218 12,433 12,172 37,823 907.0
Rhode Island 824 629 723 2,176 756.5
South Carolina 2,934 2,842 3,018 8,794 645.7
South Dakota 795 741 631 2,167 672.4
Tennessee 3,968 3,760 3,539 11,267 591.9
Texas 9,515 9,314 10,059 28,888 564.1
Utah 1,082 974 983 3,039 577.4
Vermont 387 397 392 1,176 518.3
Virginia 6,161 5,541 5,556 17,258 788.3
Washington 2,498 2,522 2,681 7,701 516.7
West Virginia 2,463 2,314 2,202 6,979 954.7
Wisconsin 4,246 4,365 4,789 13,400 670.7
Wyoming 692 686 556 1,934 1,172.1
Total 189,116 181,374 187,205 557,695 664.2
* International Classification of Diseases, Ninth Revision, Clinical Modification codes 416.0, 416.8, or 416.9 for any-listed diagnosis on Medicare hospital
claims during 2000–2002.
†Per 100,000 Medicare enrollees. Age-standardized to 2000 U.S. standard population aged >65 years.
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TABLE 21. Comparison of disease reporting classifications of pulmonary hypertension with treatment-based classifications
International Classification of Diseases, International Classification of Diseases, Revised treatment-based clinical classification
Ninth Revision (ICD-9) classification* Tenth Revision (ICD-10) classification† of pulmonary hypertension§
416.0 Primary pulmonary hypertension
• Idiopathic pulmonary arteriosclerosis
• Pulmonary hypertension (essential)
(idiopathic) (primary)
I27.0 Primary pulmonary hypertension
• Pulmonary (artery) hypertension
(idiopathic) (primary)
1. Pulmonary arterial hypertension
• 1.1. Idiopathic
• 1.2. Familial
• 1.3. Associated with
–1.3.1. Collagen vascular disease
–1.3.2. Congenital systemic-to-pulmonary shunts
–1.3.3. Portal hypertension
–1.3.4. HIV infection
–1.3.5. Drugs and toxins
–1.3.6. Other (thyroid disorders, glycogen storage
disease, Gaucher disease, hereditary hemor-
rhagic telangiectasia, hemoglobinopathies,
myeloproliferative disorders, and splenectomy)
• 1.4. Associated with significant venous or capillary
involvement:
–1.4.1. Pulmonary veno-occlusive disease
–1.4.2. Pulmonary capillary hemangiomatosis
• 1.5. Persistent pulmonary hypertension of the
newborn
2. Pulmonary hypertension with left heart disease
• 2.1. Left-sided atrial or ventricular heart disease
• 2.2. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung
diseases and/or hypoxia
• 3.1. Chronic obstructive pulmonary disease
• 3.2. Interstitial lung disease
• 3.3. Sleep-disordered breathing
• 3.4. Alveolar hypoventilation disorders
• 3.5. Chronic exposure to high altitude
• 3.6. Developmental abnormalities
4. Pulmonary hypertension attributed to chronic
thrombotic and/or embolic disease
• 4.1. Thromboembolic obstruction of proximal
pulmonary arteries
• 4.2. Thromboembolic obstruction of distal pulmo-
nary arteries
• 4.3. Nonthrombotic pulmonary embolism
5. Miscellaneous (Sarcoidosis, histiocytosis X,
lymphangiomatosis, and compression of pulmonary
vessels)
* World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death, 9th revision, vol. 1. Geneva,
Switzerland: World Health Organization; 1977.
† World Health Organization. International statistical classification of diseases and related health problems, 10th revision. Geneva, Switzerland: World Health
Organization; 1992.
§ Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43:5S–12S.
416.9 Chronic pulmonary heart disease,
unspecified
• Chronic cardiopulmonary disese
• Cor pulmonale (chronic)
416.8 Other chronic pulmonary heart
diseases
• Pulmonary hypertension, secondary
I27.9 Pulmonary heart disease, unspecified
• Chronic cardiopulmonary disease
• Cor pulmonale (chronic)
I27.8 Other specified pulmonary heart
diseases
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FIGURE 1. Age-standardized death rate* among decedents
with pulmonary hypertension as any contributing cause of
death, by sex and year — United States, 1980–2002
* Per 100,000 population. Age-standardized to the 2000 U.S. standard
population.
FIGURE 2. Age-standardized death rate* among decedents
with pulmonary hypertension as any contributing cause of
death, by race† and year — United States, 1980–2002
* Per 100,000 population. Age-standardized to the 2000 U.S. standard
population.
†Data are presented only for white and black races because rates for other
racial populations, when analyzed separately, were too small for meaningful
analysis.
FIGURE 3. Age-specific death rate* among decedents with
pulmonary hypertension as any contributing cause of death,
by age group and year — United States, 1980–2002
* Per 100,000 population. * Per 100,000 population.
FIGURE 4. Age-specific death rate* among decedents with
pulmonary hypertension as any contributing cause of death,
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* Per 100,000 population.
† Data are presented only for white and black races because rates for other
racial populations, when analyzed separately, were too small for meaningful
analysis.
FIGURE 5. Age-specific death rate* among decedents with
pulmonary hypertension as any contributing cause of death,
by race† and age group — United States, 2000–2002
FIGURE 6. Age distribution among decedents with pulmonary
hypertension as any contributing cause of death, by sex and
age group — United States, 2000–2002
FIGURE 7. Age distribution among decedents with pulmonary
hypertension as any contributing cause of death, by race*
and age group — United States, 2000–2002
* Per 100,000 population. Age-standardized to the 2000 U.S. standard
population.
FIGURE 8. Age-standardized hospital rate* for persons with
pulmonary hypertension as any-listed diagnosis, by sex and









































































* Data are presented only for white and black races because percentages
for other racial populations, when analyzed separately, were too small for
meaningful analysis.
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* Per 100,000 population.
FIGURE 9. Age-specific hospital rate* for persons with
pulmonary hypertension as any-listed diagnosis, by year and
age group — National Hospital Discharge Survey, United
States, 1980–2002
* Per 100,000 population.
FIGURE 10. Age-specific hospital rate* for persons with
pulmonary hypertension as any-listed diagnosis, by sex and
age group — National Hospital Discharge Survey, United
States, 2000–2002
* Per 100,000 Medicare enrollees. Age-standardized to the 2000 U.S.
standard population aged >65 years.
FIGURE 11. Age distribution among persons hospitalized with
pulmonary hypertension, by sex and age group — National
Hospital Discharge Survey, United States, 2000–2002
FIGURE 12. Age-standardized hospital rate* for Medicare
enrollees aged >65 years with pulmonary hypertension as any-
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FIGURE 13. Age-standardized hospital rate* for Medicare
enrollees aged >65 years with pulmonary hypertension as
any-listed diagnosis, by race† and year — United States, 1990–
2002
* Per 100,000 Medicare enrollees. Age-standardized to the 2000 U.S.
standard population aged >65 years.
† Data are presented only for white and black races because rates for other
racial populations, when analyzed separately, were too small for meaningful
analysis.
FIGURE 14. Age-specific hospital rate* for Medicare enrollees
aged >65 years with pulmonary hypertension as any-listed
diagnosis, by age group and year — United States, 1990–
2002
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